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High throughput mRNA profiling highlights associations between myocardial
infarction and aberrant expression of inflammatory molecules in blood cells
Stephanie Bezzina Wettinger, Carine J. M. Doggen, C. Arnold Spek, Frits R. Rosendaal, and Pieter H. Reitsma
Studies on the role of inflammation in
cardiovascular disease focus on surro-
gate markers like plasma levels of C-
reactive protein or interleukins that are
affected by several factors. In this study
we employ an approach in which the
inflammatory mRNA profile of leucocytes
is measured directly in a multigene sys-
tem. We investigated the mRNA profile for
35 inflammatory markers in blood samples
in a case-control study including 524 men
with a history of myocardial infarction
and 628 control subjects. Compared with
controls, patients showed mRNA profiles
with increased levels of most inflamma-
tory mRNAs. The 2 most prominent mRNA
risk indicators encoded the secreted pro-
tein macrophage migration inhibitory fac-
tor (crude odds ratio [OR], 3.4 for the
highest quartile versus the lowest quar-
tile (95% confidence interval [CI95], 2.3-
4.9), and the intracellular regulator pro-
teinase inhibitor 9 (OR, 2.5 for the highest
versus the lowest quartile (CI95, 1.8-3.5),
both showing an increase in odds ratio
with increasing quartiles. Leucocytes in
the blood of patients with myocardial
infarction are more active in transcription
of inflammatory genes, as evidenced by
mRNA profiling. These data support the
hypothesis that an inflammatory response
involving leucocytes plays a role in the
pathogenesis of myocardial infarction.
(Blood. 2005;105:2000-2006)
© 2005 by The American Society of Hematology
Introduction
Inflammation plays a key role in the pathophysiology of atheroscle-
rosis and in the development of acute coronary events.1 Activated
leucocytes, cytokines, and chemokines are prominent features of an
atherosclerotic plaque. Moreover, plasma levels of markers of
inflammation such as cell adhesion molecules, cytokines, proathero-
genic enzymes, and C-reactive protein (CRP) were found to predict
cardiovascular events in a variety of clinical settings.2 However
surrogate markers like CRP are far removed from the actual disease
process since they reflect how the liver reacts to disease in the
vasculature. Therefore, the nature of a chronic systemic inflamma-
tory state and the role of circulating leucocytes in maintaining such
a state remain unclear.
The inflammatory state of leucocytes may be the byproduct of
the local inflammation in the vessel wall, or it may reflect an active
or latent infection that is in part responsible for the atherosclerotic
process. This is supported by observations of increased neopterin
and procalcitonin levels in patients with cardiovascular disease.3-6
Whatever the mechanism, some inflammatory mediators may
directly influence the atherosclerotic process in several ways.
Interleukin 6, for example, lowers high density lipoprotein and
alters lipoprotein metabolism,7 and CRP may facilitate low-density
lipoprotein uptake by macrophages.8
Plasma protein levels do not fully reflect the inflammatory
signature of leucocytes in whole blood. Tissue leucocytes and
endothelial cells may also contribute to the plasma levels of
inflammatory markers, and many inflammatory mediators are also
produced by other cell-types. To overcome these obstacles in
assessing the inflammatory status of circulating leucocytes, we
have developed a sensitive quantitative assay that is capable of
measuring a panel of mRNA levels in large series of whole blood
samples in a single reaction. The panel was composed of target
genes encoding cytokines, chemokines, their receptors (as represen-
tatives of the soluble mediators of the inflammatory response),
genes encoding nuclear factor B (NFB) pathway components (as
representatives of the main intracellular signal transduction route
of inflammation), tissue factor (as the inducible component of the
clotting system), and genes encoding several intracellular compo-
nents involved in the link between NFB and apoptosis, a link that
is considered important for the survival of immune cells. We have
applied this novel high throughput technology in a large population-
based case-control study on myocardial infarction to assess whether
inflammatory mRNA in circulating cells is increased in patients
with myocardial infarction compared to control subjects.
Patients, materials, and methods
Patients and control subjects
Patients were men consecutively diagnosed with a first myocardial infarc-
tion before the age of 70 years between January 1990 and January 1996.
Two of the following 3 characteristics had to be identifiable in the discharge
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record or hospital charts to confirm acute myocardial infarction: typical
chest pain, electrocardiographical changes indicative of evolving myocar-
dial infarction, or a transient rise in cardiac enzymes to more than twice the
normal upper limit. Control subjects were men without a history of
myocardial infarction who had a minor orthopaedic intervention between
January 1990 and May 1996 and who had received prophylactic anticoagu-
lation treatment after this intervention. Control subjects were identified via
the Leiden Anticoagulation Clinic, which serves the same region as the
hospitals where the patients were recruited and which was responsible for
monitoring prophylactic anticoagulation for several weeks or months after
the surgery. They had not used anticoagulants for at least 6 months prior to
inclusion and control subjects were frequency matched to the patients on
10-year age groups. To ensure that inflammatory reactions surrounding the
cardiac event or orthopaedic intervention had subsided, subjects were
included in this study at least 6 months after the date of the event, or index
date. Median time between index date and blood collection was 2.8 years
(range, 0.6 years to 6.3 years) for cases and control subjects alike. Details of
the population-based case-control Study of Myocardial Infarctions Leiden
(SMILE), which included 1206 men, are described elsewhere.9
Medication use and history of diabetes prior to the index date were
ascertained by interview with control subjects and retrieved from discharge
letters for patients. At time of the blood draw they were assessed by using a
structured interview. A person was classified as hypertensive or hypercholes-
terolemic when he was prescribed specific medications for these conditions.
The study was approved by the review committee of the Leiden University
Medical Center and the subjects gave written informed consent in
accordance with institutional guidelines.
RNA analysis
Morning fasting–citrated blood samples were drawn from the antecubital
vein. Immediately thereafter, aliquots of 100 L were added to 900 L lysis
buffer.10 The samples were stored at 70°C until further use. RNA was
isolated using a silica-based method10 and analyzed by multiplex ligation–
dependent probe amplification (MLPA) using a kit developed in collabora-
tion with MRC-Holland (Amsterdam, The Netherlands) for the simulta-
neous detection of 38 messenger RNA molecules.11 This MLPA profiling
method is insensitive to the total amount of mRNA that is included in the
reaction; therefore, the profile is independent of the total white blood cell
(WBC) count. All samples were tested with the same batch of reagents, and
a negative and lipopolysaccharide-stimulated control sample were included
on each plate. The final polymerase chain reaction (PCR) fragments
amplified with carboxyfluorescein-labeled primers were separated by
capillary electrophoresis on a 16-capillary ABI-Prism 3100 Genetic Ana-
lyzer (Applied Biosystems, Nieuwerkerk aan de IJssel, The Netherlands).
Peak area and height were processed using GeneScan analysis software
(Applied Biosystems). The levels of mRNA for each gene were expressed
as a normalized ratio of the peak area divided by the peak area of a control
gene, resulting in the relative abundance of mRNAs of the genes of interest.
Our probe set is listed in Table 1 and contains probes for mRNAs of 35
inflammation- and apoptosis-related proteins and 3 control genes, B2M,
CDKN1A, and PARN. Expression levels of 2 microglobulin (B2M) were
above the upper limit of detection in all samples, whereas CDKN1A and
PARN mRNA levels were detectable in all 1152 samples and in 1135
samples, respectively. Therefore, areas were normalized to PARN and to
CDKN1A resulting in similar expression profiles. We have opted to present
the results relative to CDKN1A because of its insensitivity to in vitro
lipopolysaccharide stimulation of an inflammatory response11 (C.A.S.,
unpublished data, November, 2002).
Statistics
Because this mRNA profiling technique was not available when the SMILE
study was initiated and the samples were collected, this study was not
preceded by a sample size calculation.
The relative mRNA levels of cases and control subjects were compared
using a Mann-Whitney test. Persons with values above the upper detection
limit were assumed to have the highest levels, whereas persons with values
below the detection limit were assumed to have the lowest mRNA level for
that marker. Odds ratios (ORs) were calculated as an estimate of the relative
risk for myocardial infarction. Quartiles were defined on the basis of the
mRNA distribution among control subjects. The lowest quartile was used as
a reference category for calculating odds ratios. 95% confidence levels
(CI95) were calculated according to the method by Woolf12 or were derived
from the standard errors calculated by the logistic model. For variables with
more than a quarter of the readings below the lower limit of detection, odds
ratios were calculated for persons with detectable levels compared with
those with nondetectable levels. About three-fourths of the samples had
readings for PTP4A2 above the upper detection limit; therefore, the relative
risk of myocardial infarction was estimated by calculating the odds ratio for
persons with levels above the upper detection limit compared with those
within the detection limits. Odds ratios were adjusted for traditional
cardiovascular risk factors such as age, smoking, hypertension, hypercholes-
terolemia, diabetes, body mass index (BMI), alcohol use, and quartile of
CRP by using unconditional logistic regression. The odds ratios were
further adjusted for time between the index date and blood sampling.
Adjusted odds ratios were also calculated limited to samples drawn at least
2 years after the index date. Because 185 patients stopped smoking in the
interval between the time of their myocardial infarction and blood
withdrawal, and smoking may influence some of the inflammatory markers,
odds ratios were also calculated restricted to men who were nonsmokers
both before and after the index date. Odds ratios were also adjusted for use
of medication at time of blood sampling. Separate restriction analyses to
include only men who were not on lipid-lowering therapy, antihyperten-
sives, and aspirin at time of myocardial infarction and at time of blood
sampling were also performed.
Results
It was possible to isolate RNA and perform MLPA analysis on 524
cases and 628 control subjects that fit the criteria required for this
study. Mean age was 56.4 years (range, 32.3-70.0 years) and 57.4
years (range, 27.2-74.8 years) for patients and controls, respec-
tively. Out of the patients, 62% were smokers compared with 33%
of control subjects (Table 2).
Men with a history of myocardial infarction had higher median
leukocyte levels (normalized to CDKN1A) of most inflammatory
mRNAs compared with control subjects (Table 1). Analysis based
on mRNA levels after stratification in quartiles resulted in elevated
odds ratios (Table 3) that were not influenced much by adjustment
for traditional risk factors and plasma levels of CRP. The adjusted
odds ratios increased 2- to 3-fold for the highest versus lowest
quartiles of MIF, PI9, CCL3, PTPN1, and BMI1. PDE4B, GSTP1,
NFKB1, IL12A, PDGFB, MYC, IL1B, IL8, NFKB1A, and IL15(1)
had odds ratios between 1.5 and 1.9 after adjustment, while LTA,
IFNG, IL1RN, TNFRSF1A, IL18, and CCL4 had adjusted odds
ratios of 1.3 or 1.4. THBS1 and PARN were not associated with
myocardial infarction (adjusted OR [ORadj] 0.9 and 1.0, respec-
tively). The full data in quartiles are shown in Table 4 for those
markers that show increasing odds ratios with increasing levels
of mRNA.
Odds ratios for markers with more than a quarter of the readings
below detection levels are shown in Table 5. In this comparison of
detectable versus undetectable levels, IL15(2), MCP-2, and IL2
were associated with an approximately 2-fold increase in odds
ratio. IL12B had an adjusted odds ratio of 1.6 and IL6, TNF, IL4(2),
and IL10 had a somewhat lower adjusted odds ratio of 1.4. Too few
samples had detectable levels of IL13 and TF mRNA (9 and 15
samples, respectively). MCP-1 and NFKB2 had an odds ratio of 1.2
(CI95, 0.9-1.6 for both) and IL4 was not associated with myocar-
dial infarction. IL1A was peculiar because it gave an odds ratio
below 1, indicating a protective effect (OR, 0.6; CI95, 0.5-0.8).
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Most of the readings for PTP4A2 were above the upper detection
limit. The ORadj for persons with levels above the upper detection
limit compared with those with levels within the detection limits
was 1.7 (CI95, 1.2-2.3).
Few of the crude odds ratios were changed by adjustment for
cardiovascular risk factors, and only 7 mRNA markers (LTA, MIF,
IL1B, IL1RN, MYC, NFKB1, and CCL4) showed differences
between the crude and adjusted odds ratios greater than 0.2.
Multivariate analysis indicated that smoking accounted for most of
these differences (Tables 3 and 5). A stratified analysis showed that
the inflammatory markers have elevated odds ratios even in
nonsmokers (Tables 3 and 5), and, in most cases, the odds ratios
were higher in men who did not smoke on and after the index date
even after adjustment for traditional risk factors. This was particu-
larly striking for the highest compared with the lowest quartile of
mRNA levels of MIF with an age-adjusted odds ratio of 5.2 (95CI,
2.9-9.5) in nonsmokers.
Analysis excluding persons with levels of CRP above 10 mg/L
did not materially change the odds ratios (data not shown).
Adjustment for use of medication at time of blood sampling in the
logistic regression model had little effect on the odds ratios. Odds
ratios remained elevated even after restriction to subjects who
never used aspirin or medications for hypercholesterolemia or
hypertension. Adjustment for traditional risk factors had little effect
on these odds ratios. Time since the index date did not change the
adjusted odds ratios for the highest quartiles, except for those of
MIF, PI9, and PTPN1, which increased further to 3.5 (95CI,
2.3-5.2), 2.9 (95CI, 2.0-4.2), and 2.5 (95CI, 1.7-3.7), respectively
(Tables 3 and 5). The odds ratios of these markers were elevated
even when cases who had a myocardial infarction less than 2 years
before sample collection were excluded from the analysis (MIF, 2.0
[1.2-3.1]; PI9, 2.0 [1.3-3.0]; and PTPN1, 2.4 [1.5-3.8]). Besides the
odds ratios of MIF and PI9, in this analysis, only the odds ratios of
MYC, IL8, and IL2 decrease somewhat (Tables 3 and 5).
Table 1. Alphabetical listing of the mRNAs and median values of cases and control subjects and their range (normalized to CDKN1A)
Gene
symbol Descriptive name
Patients Controls
PMedian Range Median Range
B2M Beta-2-microglobulin NA* NA* NA* NA* NA
BMI1 BMI-1 oncogene homolog 0.84 0.09-2.18 0.76 0.00-2.41  .001
CCL3 Chemokine (C-C motif) ligand 3 0.14 0.00-0.85 0.13 0.00-1.16  .001
CCL4 Chemokine (C-C motif) ligand 4 1.30 0.23-* 1.26 0.23-* .57
CDKN1A Cyclin-dependent kinase inhibitor 1A NA NA NA NA NA
GSTP1 Glutathione S-transferase 0.31 0.00-1.36 0.29 0.00-1.05  .001
IFNG Interferon, gamma 0.16 0.00-0.80 0.15 0.00-1.78 .21
IL10 Interleukin 10 0.00 0.00-0.73 0.00 0.00-0.45 .006
IL12A Interleukin 12, subunit p35 3.04 0.16-* 2.76 0.16-*  .001
IL12B Interleukin 12, subunit p40 0.00 0.00-0.33 0.00 0.00-1.78 .06
IL13 Interleukin 13 0.00 0.00-0.26 0.00 0.0-0.08 .96
IL15 (1) Interleukin 15, transcript variants 1 and 3 0.48 0.13-2.59 0.46 0.16-2.52 .014
IL15 (2) Interleukin 15, transcript variant 2 0.00 0.00-0.26 0.00 0.00-0.08 .003
IL18 Interleukin 18 0.12 0.00-1.45 0.11 0.00-0.97 .009
IL1A Interleukin 1, alpha 0.00 0.00-0.39 0.00 0.00-0.31  .001
IL1B Interleukin 1, beta 0.99 0.24-* 0.87 0.14-*  .001
IL1RN Interleukin 1 receptor antagonist 1.90 0.54-* 1.71 0.47-*  .001
IL2 Interleukin 2 0.07 0.00-0.52 0.03 0.00-1.19  .001
IL4 (1) Interleukin 4, transcript variant 1 0.00 0.00-0.31 0.00 0.00-0.22 .79
IL4 (2) Interleukin 4, transcript variants 1 and 2 0.03 0.00-0.46 0.00 0.00-0.51  .001
IL6 Interleukin 6 0.00 0.00-0.24 0.00 0.00-0.28 .11
IL8 Interleukin 8 1.38 0.00-* 1.30 0.00-* .06
LTA Lymphotoxin alpha (Tumor necrosis factor, beta) 0.25 0.00-1.08 0.23 0.00-0.82  .001
MCP-1 Monocyte chemotactic protein, 1 0.00 0.00-8.22 0.14 0.00-0.70 .31
MCP-2 Monocyte chemotactic protein, 2 0.00 0.00-10.36 0.00 0.00-0.66 .07
MIF Macrophage migration inhibitory factor 0.91 0.00-3.95 0.75 0.00-3.98  .001
MYC v-myc oncogene homolog 1.41 0.43-* 1.25 0.28-*  .001
NFKB1 nuclear factor kappa-B, subunit 1 1.12 0.43-* 1.02 0.19-*  .001
NFKB2 nuclear factor kappa-B, subunit 2 0.00 0.00-0.29 0.00 0.00-0.20 .049
NFKBIA nuclear factor kappa-B inhibitor, alpha 2.98 0.65-* 2.66 0.55-*  .001
PARN Polyadenylate-specific ribonuclease 2.27 0.71-* 2.34 0.67-* .41
PDE4B Phosphodiesterase 4B, cAMP-specific 2.23 0.54-* 2.12 0.58-*  .001
PDGFB Platelet-derived growth factor, beta polypeptide 0.15 0.00-0.65 0.13 0.00-0.75 .002
PI9 proteinase inhibitor 9, ovalbumin type 1.81 0.24-* 1.58 0.00-*  .001
PTP4A2 Protein-tyrosine phosphatase, type 4A, 2 NA* NA* NA* NA* NA
PTPN1 Protein-tyrosine phosphatase, nonreceptor-type, 1 0.24 0.00-0.63 0.21 0.00-0.79  .001
TF Tissue factor 0.00 0.00-0.13 0.00 0.00-0.07 .54
THBS1 Thrombospondin 1 0.29 0.00-1.47 0.30 0.00-1.40 .75
TNF Tumor necrosis factor, alpha 0.00 0.00-0.32 0.00 0.00-0.21 .014
TNFRSF1A Tumor necrosis factor receptor superfamily, 1A 2.77 1.02-* 2.57 0.77-*  .001
P values are according to the (2-tailed) Mann-Whitney test.
NA indicates not applicable.
*mRNA levels above the detection limit.
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Discussion
Patients with a history of myocardial infarction have a different
mRNA signature for inflammatory markers than healthy control
subjects, with higher expression of circulating inflammatory
RNA. More specifically, increased mRNA levels of MIF, PI9,
CCL3, PTPN1, BMI1, and IL15(2) were found to be associated
with myocardial infarction, with odds ratios in the range of 2 to
3 for patients compared with control subjects. Elevated mRNA
levels of PDGFB, IL12A, IL12B, MYC, NFKB1, GSTP1, IL18,
IL15(2), IL1B, IL1RN, IL8, NFKBIA, PDE4B, MCP-2, and IL2
all yielded odds ratios for myocardial infarction varying be-
tween 1.5 and 2.
The highest odds ratio was observed for patients with high
mRNA levels of macrophage migration inhibitory factor (MIF).
Recently, this protein has been associated with an array of
autoimmune and inflammatory diseases including severe sep-
sis,13 arthritis,14 bronchial asthma,15 and acute respiratory dis-
tress syndrome.16,17 MIF counteracts the immunosuppressive
effects of glucocorticoids,18 and prolongs the inflammatory
response by inhibiting apoptosis of macrophages.19 Its plasma
levels increase up to 5-fold in the acute phase of myocardial
infarction, but decrease to levels similar to those in healthy
persons within 3 weeks. The rapid increase is thought to be due
to the production or release of MIF by necrotic tissue in the
heart, cellular infiltrate at local sites, and peripheral blood
mononuclear cells.20,21 These studies were performed on a small
number of patients and controls, and aimed at the inflammatory
response during and shortly after the myocardial event. The
major source of MIF may differ in the acute and subacute stages
of myocardial infarction.21 Our study shows that expression of
MIF in circulating cells is higher in men with myocardial
infarction even in the stable state long after the event.
PI9 was also prominently associated with myocardial infarc-
tion. This protein protects cells from apoptosis due to granzyme
B released by cytotoxic lymphocytes to kill abnormal cells.22 It
also inhibits the conversion of the inactive precursors of IL1B and
IL18 into the active forms. Its involvement in atherosclerosis
Table 2. Characteristics of patients and control subjects
Patients,
n  524
Controls,
n  628
Age, y, mean (range) 56.4 (32.3-70.0) 57.4 (27.2-74.8)
Current smokers, no. (%) 323 (61.6) 209 (33.3)
Alcohol users, no. (%) 420 (80.2) 543 (86.5)
Obesity no. (%)* 90 (17.2) 104 (16.6)
BMI, kg/m2, mean (range)* 27.1 (17.3-45.8) 26.9 (17.1-40.6)
Diabetes, no. (%) 23 (4.4) 21 (3.3)
Hypertension, no. (%)† 97 (18.5) 101 (16.1)
Hypercholesterolemia, no. (%)† 12 (2.3) 10 (1.6)
*A person was defined as obese if his BMI exceeded 30 kg/m2. Data on height
and weight were not available for 2 people.
†A person was classified as hypertensive or hypercholesterolemic if he was
taking prescription drugs for these conditions.
Table 3. Odds ratios for highest versus lowest quartile
Marker
Patients
N  524‡ Crude OR
OR
adjusted
for age and
smoking Adjusted OR*
OR for
nonsmokers only,
age corrected
N  617
OR adjusted for
traditional risk
factors and for
time since the
event
Adjusted OR* for
samples
collected more
than 2 years
after the event
N  852
OR adjusted for traditional
risk factors and for use of
medication at time of
sample collection
MIF 193 3.4 (2.3-4.9) 3.1 (2.1-4.5) 3.0 (2.0-4.4) 5.2 (2.9-9.5) 3.5 (2.3-5.2) 2.0 (1.2-3.1) 3.2 (2.1-4.9)
PI9 195 2.5 (1.8-3.5) 2.5 (1.8-3.6) 2.6 (1.8-3.8) 3.1 (1.8-5.3) 2.9 (2.0-4.2) 2.0 (1.3-3.0) 2.7 (1.8-4.1)
CCL3 183 2.2 (1.5-3.0) 2.2 (1.5-3.1) 2.3 (1.6-3.3) 2.8 (1.7-4.6) 2.3 (1.6-3.3) 2.5 (1.6-3.8) 2.4 (1.6-3.5)
PTPN1 170 2.3 (1.6-3.3) 2.2 (1.5-3.2) 2.2 (1.5-3.2) 3.6 (2.1-6.2) 2.5 (1.7-3.7) 2.4 (1.5-3.8) 2.2 (1.4-3.2)
BMI1 159 1.9 (1.3-2.7) 1.8 (1.3-2.6) 2.0 (1.4-2.9) 1.7 (1.0-2.8) 2.1 (1.4-3.0) 1.9 (1.3-3.0) 2.0 (1.3-3.0)
PDE4B 162 1.9 (1.3-2.6) 1.9 (1.3-2.7) 1.9 (1.3-2.8) 2.7 (1.6-4.6) 2.2 (1.5-3.2) 1.9 (1.2-2.9) 1.9 (1.3-2.8)
GSTP1† 162 1.9 (1.3-2.6) 1.7 (1.2-2.4) 1.8 (1.2-2.5) 1.7 (1.0-2.8) 1.6 (1.1-2.4) 1.9 (1.2-2.9) 1.9 (1.2-2.8)
NFKB1 182 2.0 (1.4-2.8) 1.7 (1.2-2.5) 1.7 (1.2-2.4) 2.0 (1.2-3.3) 1.8 (1.2-2.6) 1.5 (1.0-2.3) 1.4 (1.0-2.1)
IL12A 165 1.8 (1.3-2.5) 1.7 (1.2-2.5) 1.7 (1.2-2.4) 2.2 (1.3-3.6) 1.7 (1.2-2.4) 1.9 (1.3-3.0) 1.6 (1.1-2.4)
PDGFB 156 1.6 (1.1-2.2) 1.6 (1.1-2.3) 1.7 (1.2-2.4) 1.3 (0.8-2.2) 1.8 (1.2-2.6) 1.5 (0.9-2.3) 1.7 (1.2-2.6)
MYC 182 2.0 (1.4-2.8) 1.5 (1.1-2.2) 1.6 (1.1-2.3) 1.6 (1.0-2.6) 1.5 (1.1-2.2) 1.1 (0.7-1.7) 1.4 (0.9-2.0)
IL1B 193 2.0 (1.5-2.9) 1.8 (1.2-2.5) 1.6 (1.1-2.3) 2.7 (1.6-4.5) 1.6 (1.1-2.2) 1.7 (1.1-2.6) 1.7 (1.2-2.5)
IL8 152 1.6 (1.1-2.2) 1.5 (1.1-2.1) 1.6 (1.1-2.3) 2.0 (1.2-3.3) 1.7 (1.2-2.4) 1.2 (0.8-1.9) 1.6 (1.1-2.4)
NFKBIA 174 1.7 (1.2-2.3) 1.6 (1.1-2.2) 1.5 (1.0-2.1) 1.9 (1.2-3.1) 1.4 (1.0-2.0) 1.3 (0.9-2.0) 1.6 (1.1-2.3)
IL15(1) 140 1.4 (1.0-2.0) 1.5 (1.0-2.1) 1.5 (1.0-2.2) 1.5 (0.9-2.6) 1.5 (1.0-2.1) 1.4 (0.9-2.1) 1.3 (0.8-1.9)
LTA 163 1.7 (1.2-2.3) 1.3 (0.9-1.9) 1.4 (1.0-2.0) 1.4 (0.8-2.3) 1.3 (0.9-2.0) 1.4 (0.9-2.1) 1.4 (1.0-2.1)
IFNG 146 1.3 (0.9-1.8) 1.4 (1.0-2.0) 1.4 (1.0-2.1) 1.5 (0.9-2.4) 1.4 (1.0-2.0) 1.4 (0.9-2.2) 1.4 (1.0-2.1)
IL1RN 160 1.7 (1.2-2.3) 1.4 (1.0-2.0) 1.3 (0.9-1.9) 1.4 (0.8-2.3) 1.3 (0.9-1.9) 1.3 (0.8-1.9) 1.1 (0.8-1.7)
TNFRSFIA 153 1.4 (1.0-2.0) 1.4 (1.0-1.9) 1.3 (0.9-1.8) 1.9 (1.2-3.1) 1.3 (0.9-1.8) 2.0 (1.3-3.0) 1.2 (0.8-1.8)
IL18 134 1.3 (0.9-1.8) 1.3 (0.9-1.8) 1.3 (0.9-1.9) 1.5 (0.9-2.4) 1.3 (0.9-1.9) 2.0 (1.3-3.2) 1.3 (0.9-2.0)
CCL4 135 1.0 (0.7-1.4) 1.2 (0.9-1.8) 1.3 (0.9-1.9) 0.9 (0.6-1.5) 1.3 (0.9-1.8) 1.5 (1.0-2.3) 1.5 (1.0-2.2)
THBSI 126 0.9 (0.6-1.2) 0.9 (0.7-1.3) 0.9 (0.6-1.3) 0.7 (0.5-1.2) 1.0 (0.7-1.4) 1.2 (0.8-1.8) 0.9 (0.6-1.4)
PARN 117 0.8 (0.6-1.2) 1.0 (0.7-1.4) 1.0 (0.7-1.5) 0.7 (0.4-1.1) 1.0 (0.7-1.4) 1.3 (0.8-1.9) 1.0 (0.7-1.5)
Number of cases in the highest quartiles are shown in column 2. Results of a stratified analysis on men who were nonsmokers both at the index date and the sampling date
are shown in column 6 after adjustment for age. Subsequent columns show odds ratios adjusted for traditional risk factors and for time since the event (column 7), adjusted
odds ratios using only samples collected more than 2 years after the event (column 8), and adjustment for use of medication at time of sample collection (last column). 95%
confidence intervals are shown in parentheses.
*Adjusted for age, smoking, use of medication for hypertension and hypercholesterolemia, diabetes, BMI, alcohol habit, and quartile of CRP.
†Out of 518 cases and 597 controls.
‡The number of controls in each quartile is 157 except for GSTP1. These numbers apply when restrictions are not used.
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has been suggested by its altered expression in atherosclerotic
lesions.23 The present finding of increased expression in the
circulation of men with a history of myocardial infarction adds
evidence to this and suggests that it may exert an influence
outside the plaque itself.
The absence of a noticeable effect of adjustment or of restric-
tions to people on particular groups of medication shows that these
associations are not brought about by traditional risk factors or by
medication use. The only cardiovascular risk factor that had an
effect on some of the odds ratios (LTA, MIF, IL1B, IL1RN, MYC,
NFKB1, and CCL4) was smoking. This finding is not surprising
since it is generally accepted that smoking enhances vascular
inflammation, and some systemic inflammatory markers, including
CRP, are higher in smokers than former or never smokers.24,25 The
results of the stratified analysis on nonsmokers show that the
inflammatory markers have an effect themselves, and that smoking
masked some of this effect.
Adjustment for levels of CRP did not change the odds ratios.
This underlines that in cardiovascular disease inflammation plays a
role in 3 compartments. The first is in the inflamed vascular wall
where many inflammatory cells are known to accumulate. The
second is in the liver where acute phase reactants such as CRP are
synthesized, most likely in response to cytokines that are produced
elsewhere in the body. The results from our study indicate that there
is a third inflammatory compartment in circulating leucocytes.
Apparently, the relationship between events in leucocytes on the
one hand and acute-phase protein production in the liver on the
other, if there is any, is not a simple one.
In quantitative or semiquantitative mRNA profiling methods
accuracy is generally poor. As described in our original methods
paper reproducibility of the MLPA using independent duplicate
samples was satisfactory: interassay correlation between 3 represen-
tative data sets of independent samples was 0.96 and intra-assay
variation between 4 independent samples was 0.97.11 With respect
to the reproducibility of the presented profiling results we would
like to add the following. Based on the repeat measurements of the
lipopolysaccharide samples in the present study we find coeffi-
cients of variation for individual mRNA species of around 0.25.
Second, we recently measured a second mRNA profile, centered on
the expression of members of the Toll-like receptor family of proteins, in
the SMILE samples (S.B.W., P.R.H., unpublished results, April 2004).
PI9, MIF, and PARN were also included in the second study, and we
were able to replicate the findings reported here.
Our study evaluated mRNA-based profiles in a case-control
design. The inflammatory profile that we have observed may
reflect a chronic inflammatory state in circulating blood cells
that is predictive for myocardial infarction. Alternatively, it may
be a result of the myocardial infarction itself either directly,
since several of the mRNA markers that we assessed may also
increase during the acute phase of a myocardial infarction
(TNFA,26 IL627; IL1RN and IL1028; MIF 20,21), or indirectly
through decreased left ventricular function in myocardial infarc-
tion patients,29 a variable that was not assessed in the SMILE
study. Support for the hypothesis that we may indeed be dealing
with causative risk factors comes from the observation that the
increased odds ratios were observed in blood samples drawn at
least 6 months (median, 2.8 years) after the index date, and from
the observation that time since the event did not decrease the
odds ratios. In any case, an inflammatory state of cells in the
circulation may well have implications on the outcome and
progress of inflammation-related diseases.
After the human genome effort, gene expression profiling is
rapidly developing into a powerful tool. It has shown promising
results in identifying patterns of aberrant expression in cancer
patients, and in determining subtypes of leukemias.30 These
studies have been based on microarray techniques that, due to
their cost, have limited analysis to typically tens of samples. To
study more complex diseases a substantially larger number of
samples need to be analyzed to get reproducible and meaningful
results. The present RNA profiling study utilizes more than 1000
samples to study myocardial infarction, the largest number of
samples for such a study to date. This greatly reduces noise and
effects of factors not directly related to the disease and it also
decreases the chances of false positives, which is a major
problem in microarray studies.
In conclusion, this study presents the direct measurement of
molecular signatures from more than 30 inflammatory genes in
almost 1200 individuals. These large-scale mRNA measure-
ments give direct insight into the inflammatory status of
circulating leucocytes without the limitations of the more
common measurements of CRP and cytokine/chemokine levels
in blood or other smaller RNA studies. Leucocytes in the blood
of patients with myocardial infarction are more active in
transcription of inflammatory genes. Our results therefore
Table 4. Odds ratios with increasing quartiles of mRNA levels for a
selection of markers
Inflammatory
marker Quartile
Patients
N  524
Controls
N  628 Crude OR
Adjusted
OR*
MIF 1 57 157 1 1
2 131 157 2.3 (1.6-3.4) 2.1 (1.4-3.2)
3 143 157 2.5 (1.7-3.7) 2.4 (1.6-3.6)
4 193 157 3.4 (2.3-4.9) 3.0 (2.0-4.4)
PI9 1 78 157 1 1
2 106 157 1.4 (1.0-2.0) 1.4 (1.0-2.1)
3 145 157 1.9 (1.3-2.6) 1.8 (1.2-2.6)
4 195 157 2.5 (1.8-3.5) 2.6 (1.8-3.8)
PTPN1 1 73 157 1 1
2 122 157 1.7 (1.2-2.4) 1.7 (1.1-2.4)
3 159 157 2.2 (1.5-3.2) 2.0 (1.4-2.9)
4 170 157 2.3 (1.6-3.3) 2.2 (1.5-3.2)
PDGFB 1 98 157 1 1
2 124 157 1.3 (0.9-1.8) 1.3 (0.9-1.9)
3 146 157 1.5 (1.1-2.1) 1.5 (1.0-2.1)
4 156 157 1.6 (1.1-2.2) 1.7 (1.2-2.4)
IL12A 1 92 157 1 1
2 126 157 1.4 (1.0-1.9) 1.3 (0.9-1.9)
3 141 157 1.5 (1.1-2.2) 1.4 (1.0-2.1)
4 165 157 1.8 (1.3-2.5) 1.7 (1.2-2.4)
NFKB1 1 90 157 1 1
2 108 157 1.2 (0.8-1.7) 1.2 (0.8-1.7)
3 144 157 1.6 (1.1-2.3) 1.4 (1.0-2.1)
4 182 157 2.0 (1.4-2.8) 1.7 (1.2-2.4)
MYC 1 91 157 1 1
2 96 157 1.0 (0.7-1.5) 1.0 (0.7-1.4)
3 155 157 1.7 (1.2-2.4) 1.5 (1.0-2.1)
4 182 157 2.0 (1.4-2.8) 1.6 (1.1-2.3)
LTA 1 97 157 1 1
2 107 157 1.1 (0.8-1.6) 1.0 (0.7-1.5)
3 157 157 1.6 (1.2-2.3) 1.3 (0.9-1.9)
4 163 157 1.7 (1.2-2.3) 1.4 (1.0-2.0)
95% confidence intervals are shown in parentheses. The 1st quartile is always
the reference category.
*Adjusted for age, smoking, use of medication for hypertension or hypercholes-
terolemia, diabetes, BMI, alcohol habit, and quartile of CRP.
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represent a further step in demonstrating that inflammation in
activated leukocytes is a hallmark in the etiology of cardiovascu-
lar disease.
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